Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID: SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * * Welcome to STN International
NEWS
                 Web Page for STN Seminar Schedule - N. America
NEWS
         JAN 02
                 STN pricing information for 2008 now available
NEWS 3
         JAN 16
                 CAS patent coverage enhanced to include exemplified
                 prophetic substances
                 USPATFULL, USPAT2, and USPATOLD enhanced with new
NEWS 4 JAN 28
                 custom IPC display formats
NEWS 5 JAN 28
                 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days
                 of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current
                 U.S. National Patent Classification
NEWS 14 MAR 31
                 IFICDB, IFIPAT, and IFIUDB enhanced with new custom
                 IPC display formats
NEWS 15
         MAR 31 CAS REGISTRY enhanced with additional experimental
                 spectra
NEWS 16
         MAR 31
                 CA/CAplus and CASREACT patent number format for U.S.
                 applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31
                 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
             AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS LOGIN
              Welcome Banner and News Items
NEWS IPC8
              For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:05:32 ON 10 APR 2008

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE Do you want to switch to the Registry File? Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 12:06:02 ON 10 APR 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by ${\tt InfoChem.}$

STRUCTURE FILE UPDATES: 9 APR 2008 HIGHEST RN 1013298-21-9 DICTIONARY FILE UPDATES: 9 APR 2008 HIGHEST RN 1013298-21-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10553957X.str

```
chain nodes :
14 15 16 17 18 26 27 28 29 30 31 32 39
ring nodes :
1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 10 \quad 11 \quad 12 \quad 13 \quad 20 \quad 21 \quad 22 \quad 23 \quad 24 \quad 25 \quad 33 \quad 34 \quad 35 \quad 36
37 38
chain bonds :
5-18 11-14 14-15 15-16 16-17 16-29 17-32 21-30 22-26 26-27 27-28 28-32
30-31 32-39 33-39
ring bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-7 \quad 5-6 \quad 5-9 \quad 6-7 \quad 7-10 \quad 8-9 \quad 8-13 \quad 9-10 \quad 10-11 \quad 11-12 \quad 12-13
20 - 21 \quad 20 - 25 \quad 21 - 22 \quad 22 - 23 \quad 23 - 24 \quad 24 - 25 \quad 33 - 34 \quad 33 - 38 \quad 34 - 35 \quad 35 - 36 \quad 36 - 37 \quad 37 - 38
exact/norm bonds :
5-6 5-9 11-14 16-29 21-30 22-26
exact bonds :
5-18 7-10 14-15 15-16 16-17 17-32 26-27 27-28 28-32 30-31 32-39 33-39
normalized bonds :
1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-7 \quad 6-7 \quad 8-9 \quad 8-13 \quad 9-10 \quad 10-11 \quad 11-12 \quad 12-13 \quad 20-21 \quad 20-25
21 - 22 \quad 22 - 23 \quad 23 - 24 \quad 24 - 25 \quad 33 - 34 \quad 33 - 38 \quad 34 - 35 \quad 35 - 36 \quad 36 - 37 \quad 37 - 38
isolated ring systems :
containing 1 : 20 : 33 :
```

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:CLASS

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 12:06:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> S L1 SSS FULL

FULL SEARCH INITIATED 12:06:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 304 TO ITERATE

100.0% PROCESSED 304 ITERATIONS 6 ANSWERS

SEARCH TIME: 00.00.01

L3 6 SEA SSS FUL L1

=> FIL HCAPLUS

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'HCAPLUS' ENTERED AT 12:06:43 ON 10 APR 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2008 VOL 148 ISS 15 FILE LAST UPDATED: 9 Apr 2008 (20080409/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L3

L4 12 L3

=> S L4 AND DEBENZYLATION

8545 DEBENZYLATION 17 DEBENZYLATIONS 8551 DEBENZYLATION

(DEBENZYLATION OR DEBENZYLATIONS)

L5 4 L4 AND DEBENZYLATION

=> S L4 AND CATALYST

797619 CATALYST 794377 CATALYSTS 1020841 CATALYST

(CATALYST OR CATALYSTS)

L6 5 L4 AND CATALYST

=> S L5 AND HYDROGENATIOHN

0 HYDROGENATIOHN

L7 0 L5 AND HYDROGENATIOHN

=> S L5 AND HYDROGENATION

180450 HYDROGENATION 2396 HYDROGENATIONS 180697 HYDROGENATION

(HYDROGENATION OR HYDROGENATIONS)

L8 1 L5 AND HYDROGENATION

=> S L6 AND HYDROGENATION

180450 HYDROGENATION 2396 HYDROGENATIONS 180697 HYDROGENATION

(HYDROGENATION OR HYDROGENATIONS)

L9 2 L6 AND HYDROGENATION

=> d 15 ibib abs hitstr tot

L5 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:845541 HCAPLUS

DOCUMENT NUMBER: 145:505330

TITLE: Synthesis of carvedilol via method which inhibits

formation of impurities

INVENTOR(S): Byun, Il Suk; Chang, Suk Ku; Kim, Wan Joo; Kim, Young

Youn; Lee, Woo Hwa; Oh, Chun Rim; Ryu, Jung Bok

PATENT ASSIGNEE(S): Chemtech Research Incorporation, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given

CODEN: KRXXA7

DOCUMENT TYPE: Patent LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005003764 PRIORITY APPLN. INFO.:	A	20050112	KR 2003-45256 KR 2003-45256	20030704 20030704

AB A method for preparing carvedilol [i.e., 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol] is provided, thereby inhibiting formation of impurities. The highly pure product is useful for the treatment of hypertension. The method for preparing carvedilol thus comprises the reaction of a 1-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanone derivative with 9H-4-hydroxycarbazole. The resulting intermediate then reduced and debenzylated to give the target compound The debenzylation of the reduced intermediate is carried out using a catalyst in presence of base, such as potassium carbonate, sodium carbonate, potassium hydride or sodium hydride.

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol via method which inhibits formation of impurities using [(methoxyphenoxy)ethyl]amino]propanone derivative and (hydroxy)carbazole as reactants and reaction sequence involving alkylation, reduction and debenzylation)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L5 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1260624 HCAPLUS

DOCUMENT NUMBER: 144:22806

TITLE: Process for the preparation of carvedilol INVENTOR(S): Kankan, Rajendra Narayanrao; Rao, Dharmaraj

Ramachandra

PATENT ASSIGNEE(S): Cipla Limited, India; Wain, Christopher Paul

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	PATENT NO.			KIND DATE			APPLICATION NO.						DATE				
WO	2005	1135	 02		 A1	_	2005	1201							2	20050	 519
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	ΒA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	KP,	KR,	KΖ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,
		NG,	NI,	ио,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,
							•									VN,	
			ZM,		•	·	·	·	·	·	•	,	•	·		,	·
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
							•					-				DE,	
																PL,	
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GO,	GW,	ML,
		•	NE,	•	•	,	'	_ ,	,	,	,	,	,	,	- ~ /		,
AU	2005	•					2005	1201		AU 2	005-	2451	82		2	20050	519
	2566															20050	519
EP	1756	057			A1		2007	0228		EP 2	005-	7441	87		2	20050	519
																HU,	
		,				,	MC,									,	,
JP	2007															20050	519
	2006															20061	107
PRIORIT																20040	
	ICICITII IIII III.															20050	
OTHER SOURCE(S): CASE				REAC	CT 14	4 : 22					. •						

GI

AB A process for the preparation of carvedilol I (R = H) was disclosed and comprised aromatization/reduction of 1,2,3,9-tetrahydro-4H-carbazol-4-one by refluxing with Raney Ni and NaOH in water for 20 h to form 4-hydroxy-9H-carbazole, reaction of resulting alc. with epichlorohydrin using tetrabutylammonium bromide and NaOH in water to give 4-oxiranylmethoxy-9H-carbazole, reaction of the intermediate epoxide with MeO-2-C6H4O(CH2)2NHCH2Ph using K2CO3 in water to give carvedilol N-benzyl derivative I (R = CH2Ph), and finally, debenzylation of I (R = CH2Ph) using Pd/C in EtOAc and water to give the desired carvedilol. This invention further provided carvedilol prepared by the disclosed process, and pharmaceutical compns. containing the same, for therapeutic uses, such as adrenergic β -receptor antagonists, vasodilators and treatment of angina pectoris.

Ι

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol for use in pharmaceutical compns. as adrenergic β -receptor antagonists and vasodilators useful for the treatment of hypertension and angina pectoris)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 2-A

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-

[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
----
                        A1 20041229 WO 2004-IN52
    WO 2004113296
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
            SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
            TD, TG
                                           IN 2003-MU647
US 2005-553957
2003-MI647
A 20030620
    IN 2003MU00647
                               20050211
                                          IN 2003-MU647
    US 20060270858
                        A1
                               20061130
PRIORITY APPLN. INFO.:
                                           IN 2003-MU721 A 20030717
WO 2004-IN52 W 20040304
                                           WO 2004-IN52
OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675
GΙ
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol(I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9Hcarbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous

layer was separated, and the product enriched organic layer was washed with water $\ensuremath{\mathsf{wat}}$

till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature 60-70° for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 224782-73-4P, (S)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol 224782-76-7P,

(R)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 224782-73-4 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 72955-94-3P, N-Benzylcarvedilol

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl) benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 2-A

OMe

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN

2001:747162 HCAPLUS ACCESSION NUMBER:

135:288690 DOCUMENT NUMBER:

TITLE: Intermediates for preparing the R- or S- enantiomer

and N-benzyl derivatives of 1-[9'H-carbazol-4'-yloxy]-

3-[2"-(2"'-methoxyphenoxy)ethylamino]propan-2-ol

[carvedilol]

Ratkai, Zoltan; Barkoczy, Jozsef; Simig, Gyula; INVENTOR(S):

Gregor, Tamas; Vereczkey, Gyoergyi Donath; Nemeth, Norbert; Nagy, Kalman; Cselenyak, Judit; Szabo, Tibor; Balazs, Laszlo; Doman, Imre; Greff, Zoltan; Nagy,

Peter Kotay; Seres, Peter

PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.

SOURCE: Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1142874 EP 1142874	A2 A3	20011010 20031022	EP 2001-111214	19981124
R: BE, DE, ES,	FR, GB,	IT, SI,	LT, LV, RO	
HU 9802180	A1	20001228	HU 1998-2180	19981001
RU 2216539	C2	20031120	RU 1998-120700	19981118
RU 2245875	C2	20050210	RU 2003-107772	19981118
EP 918055	A1	19990526	EP 1998-122114	19981124
EP 918055	B1	20030423		
EP 918055	B2	20060426		
R: AT, BE, CH,	DE, DK,	ES, FR,	GB, GR, IT, LI, LU,	NL, SE, MC, PT,
IE, SI, LT,	LV, FI,	, RO		
PRIORITY APPLN. INFO.:			HU 1997-2209	A 19971124
			HU 1998-2180	A 19981001
			EP 1998-122114	A3 19981124
			RU 1998-120700	A 19981118

OTHER SOURCE(S): CASREACT 135:288690

AB R-(+)-1-[N-benzyl-2'-[[2''-(methoxyphenoxy)ethyl]amino]-3-[9'''H-carbazol-4'''-yloxy]propan-2-ol and S-(-)-1-[N-benzyl-2'-[[2''-(methoxyphenoxy)ethyl]amino]-3-[9'''H-carbazol-4'''-yloxy]propan-2-ol and the R- or S- enantiomer of carvedilol are prepared in high yield and selectivity by the ring-opening cleavage of the resp. R- or S- enantiomer of 4-(oxiranylmethoxy)-9H-carbazole with N-2-[(2'-methoxyphenoxy)ethyl]benzylamine to give the N-benzyl derivs., and the chiral carvedilol enantiomers are prepared by the reductive debenzylation of the resp. chiral N-benzyl derivs. in the presence of Pd/C and hydrazine hydrate.

IT 224782-76-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediates for preparing the R- or S- enantiomer and N-benzyl derivs. of 1-[9'H-carbazol-4'-yloxy]-3-[2"-(2"'-methoxyphenoxy)ethylamino]propa n-2-ol [carvedilol])

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT 224782-73-4DP, acid-addition salts 224782-73-4P
 224782-76-7DP, acid-addition salts
RL: SPN (Synthetic preparation); PREP (Preparation)
 (intermediates for preparing the R- or S- enantiomer and N-benzyl derivs.
 of 1-[9'H-carbazol-4'-yloxy]-3-[2"-(2"'-methoxyphenoxy)ethylamino]propa
 n-2-ol [carvedilol])
RN 224782-73-4 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm
 ethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-73-4 HCAPLUS


CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d 16 ibib abs hitstr tot

L6 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:397789 HCAPLUS

DOCUMENT NUMBER: 148:239026

TITLE: A cost effective process for production of carvedilol

INVENTOR(S): Shankar, Sanganabhatla; Pandurang, Suryavanshi

Jitendra; Moorthy, Koduru Ramanarasimha

PATENT ASSIGNEE(S): Wanbury Limited, India SOURCE: Indian Pat. Appl., 8pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00771 PRIORITY APPLN. INFO.:	A	20060825	IN 2006-MU771 IN 2006-MU771	20060522 20060522

OTHER SOURCE(S): CASREACT 148:239026

AB A cost effective process for preparation of highly pure carvedilol substantially free from impurities is described herein; 1-[carbazolyl-(4)-oxy]-3-[N-benzyl-2-(2-methoxyphenoxy)-ethylamino]-propan-2-ol is catalytically hydrogenated using inexpensive catalyst like Raney Nickel and isolating crude carvedilol free from penultimate and other major impurity; which is purified in an Et acetate/methyl Et ketone to obtain pure Carvedilol.

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(a cost effective process for production of carvedilol)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 2-A

L6 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:845541 HCAPLUS

DOCUMENT NUMBER: 145:505330

TITLE: Synthesis of carvedilol via method which inhibits

formation of impurities

INVENTOR(S): Byun, Il Suk; Chang, Suk Ku; Kim, Wan Joo; Kim, Young

Youn; Lee, Woo Hwa; Oh, Chun Rim; Ryu, Jung Bok

PATENT ASSIGNEE(S): Chemtech Research Incorporation, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given

CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Facent Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005003764	A	20050112	KR 2003-45256	20030704

PRIORITY APPLN. INFO.:

KR 2003-45256

20030704

AB A method for preparing carvedilol [i.e., 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol] is provided, thereby inhibiting formation of impurities. The highly pure product is useful for the treatment of hypertension. The method for preparing carvedilol thus comprises the reaction of a 1-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanone derivative with 9H-4-hydroxycarbazole. The resulting intermediate then reduced and debenzylated to give the target compound The debenzylation of the reduced intermediate is carried out using a catalyst in presence of base, such as potassium carbonate, sodium carbonate, potassium hydride or sodium hydride.

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol via method which inhibits formation of impurities using [(methoxyphenoxy)ethyl]amino]propanone derivative and (hydroxy)carbazole as reactants and reaction sequence involving alkylation, reduction and debenzylation)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L6 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-

[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	PATENT NO.					KIND DATE				APPLICATION NO.						DATE		
WO 200	41132	96		A1 20041229			WO 2004-IN52						20040304					
W :	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,		
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,		
	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
RV	I: BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,		
	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,		
	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,		
	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,		
	TD,	ΤG																
IN 200	00UME	647		Α		2005	0211	IN 2003-MU647						20030620				
US 200	60270	858		A1		2006	1130		US 2	005-	5539	57		2	0051	019		
PRIORITY A	PLN.	INFO	.:						IN 2	003-	MU64	7		A 2	0030	620		
									IN 2	003-	MU72	1		A 20030717				
									WO 2	004-	IN52		,	W 2	0040	304		
OTHER SOURC	THER SOURCE(S):				CASREACT 142:93675; MARPAT 142:93675													

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof

with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to 70-75° for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and

the

product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at $3.5-4.5~{\rm Kg/cm2}$ at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 224782-73-4P, (S)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol 224782-76-7P, (R)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 224782-73-4 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

72955-94-3P, N-Benzylcarvedilol ΙT RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN

72955-94-3 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm CN ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:556143 HCAPLUS

DOCUMENT NUMBER: 137:125080

TITLE: Process for preparing heterocyclic indene analogs by

cyclocarbonylation at moderate temperatures and

catalyst loading

INVENTOR(S): Scalone, Michelangelo; Zeibig, Thomas Albert

PATENT ASSIGNEE(S): Hoffmann-LaRoche Inc., Switz. SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.												DATE				
US	2002	0099.	223		A1		2002				2002-						
US	6777	559			В2		2004	0817									
CA	2434	408			A1		2002	0801		CA	2002-	2434	408		2	0020	122
WO	2002	0590	89		A2		2002	0801		WO	2002-	EP58	3		2	0020	122
WO	2002	0590	89		А3		2002	1031									
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	ΒA,	BB	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC	, EE,	ES,	FΙ,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JΡ,	KE	, KG,	ΚP,	KR,	KΖ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN	, MW,	MX,	MΖ,	NO,	NΖ,	PH,	PL,
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL	, TJ,	TM,	TR,	TT,	TZ,	UA,	UG,
		UZ,	VN,	YU,	ZA,	ZW											
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	ΑT,	BE,	CH,
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE	, IT,	LU,	MC,	NL,	PT,	SE,	TR,
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ	, GW,	ML,	MR,	ΝE,	SN,	TD,	TG
AU	2002	2476	45		A1		2002	0806		AU	2002-	2476	45		2	0020	122
EP	1355	880			A2		2003	1029		EΡ	2002-	7166	73		2	0020	122
											, IT,						
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL	, TR						
JP	2004	5194	65		T		2004	0702		JΡ	2002-	5593	91		2	0020	122
JP	4056	883			В2		2008	0305									
IN	2003	CN01	126		A		2005	0422		IN	2003-	CN11	26		2	0030	722
MX	2003	PA06	606		A		2003	0922		ΜX	2003-	PA66	06		2	0030	723
											2004-						
	7169																
PRIORIT										EΡ	2001-	1015	84		A 2	0010	125
										US	2002-	5446	2		A3 2	0020	122
											2002-					0020	
OTHER SO	OURCE	(S):			CASI	REAC	T 13	7:12									

10553957

AB A process for the preparation heterocyclic indene analogs, especially with the preparation

of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification This process avoids high temps. and

high catalyst loadings.

IT 72955-94-3P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; process for preparing heterocyclic indene analogs by cyclocarbonylation at moderate temps. and catalyst loading)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT:

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

10553957

ACCESSION NUMBER: 1994:270010 HCAPLUS

DOCUMENT NUMBER: 120:270010

TITLE: Synthesis of the enantiomers and three racemic

metabolites of Carvedilol labeled to high specific

activity with tritium

AUTHOR(S): Senderoff, S. G.; Villani, A. J.; Landvatter, S. W.;

Garnes, K. T.; Heys, J. R.

CORPORATE SOURCE: Dep. Synth. Chem., SmithKline Beecham Pharm., King of

Prussia, PA, 19406, USA

SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals

(1993), 33(12), 1091-105

CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal LANGUAGE: English

GΙ

AΒ Carvedilol (SK&F 105517) (I) possesses unique cardiovascular activity, and is under development for indications such as angina and hypertension. Tritium labeled enantiomers of Carvedilol and racemates of three metabolites were needed for pharmacol. and drug metabolic studies. These compds. were synthesized by catalytic tritium-halogen exchange using tritium gas and 10% palladium-on-carbon catalyst. The precursors were polyhalogenated in the carbazole ring. electrophilic bromination of the enantiomers of Carvedilol gave precursors that were converted to the corresponding tritiated final products by catalytic tritium halogen exchange. Bromination of 4-(2,3-epoxypropyloxy)-9H-carbazole gave an intermediate that was converted to the halogenated precursors of the racemic metabolites. Elaboration of this intermediate, 1,3,6-tribromo-4-(2,3-epoxypropyloxy)-9H-carbazole, to the desired metabolite precursors was achieved by nucleophilic epoxide opening with suitably functionalized N-benzyl aryloxyethylamines. Catalytic tritium-halogen exchange upon the brominated metabolite precursors was accompanied by cleavage of N- and O-benzyl protecting groups. Radiochem. purities of all tritiated final products were greater than 98% after preparative HPLC. Specific activities of the final products, determined by mass spectrometry, ranged from 35 to 76 Ci/mmol. Optical purity of the Carvedilol enantiomers, determined by chiral HPLC, was greater than 99%.

IT 154582-54-4P 154582-58-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

Ι

(intermediate in preparation of tritium labeled Carvedilol)

RN 154582-54-4 HCAPLUS

CN Phenol, 3-[2-[[2-hydroxy-3-[(1,3,6-tribromo-9H-carbazol-4-

yl)oxy]propyl](phenylmethyl)amino]ethoxy]-4-methoxy- (CA INDEX NAME)

PAGE 2-A

RN 154582-58-8 HCAPLUS

CN Phenol, 4-[2-[[2-hydroxy-3-[(1,3,6-tribromo-9H-carbazol-4-yl)oxy]propyl](phenylmethyl)amino]ethoxy]-3-methoxy- (CA INDEX NAME)

PAGE 2-A

IT 154582-61-3P

RN 154582-61-3 HCAPLUS

CN Phenol, 3-[2-[[3-(9H-carbazol-4-yl-1,3,6-t3-oxy)-2-hydroxypropyl](phenylmethyl)amino]ethoxy]-4-methoxy- (9CI) (CA INDEX NAME)

PAGE 2-A

=> d 18 ibib abs hitstr tot

ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-

[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol

Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev; Thennati, Rajamannar INVENTOR(S):

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

PCT Int. Appl., 27 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                    KIND DATE APPLICATION NO. DATE
    W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
           CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
           GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
           LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
           NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
           TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
           BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
           ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
           SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
           TD, TG
    IN 2003MU00647
                            20050211
                                       IN 2003-MU647
                                                            20030620
                       Α
    US 20060270858
                      A1
                            20061130
                                       US 2005-553957
                                                            20051019
PRIORITY APPLN. INFO.:
                                       IN 2003-MU647
                                                       A 20030620
                                       IN 2003-MU721
                                                        A 20030717
                                       WO 2004-IN52
                                                        W 20040304
OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

The present invention provides a process for preparation of AB 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol(I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 q (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9Hcarbazole were added and the reaction mixture was heated to $70-75^{\circ}$ for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous

layer was separated, and the product enriched organic layer was washed with water

till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature $60-70\,^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 224782-73-4P, (S)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-

3-[(9H-carbazol-4-yl)oxy]propan-2-ol 224782-76-7P,
 (R)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)
RN 224782-73-4 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

TT 72955-94-3P, N-Benzylcarvedilol
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carvedilol by amination of oxiranylmethoxycarbazole with

N-(methoxyphenoxyethyl) benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 19 ibib abs hitstr tot

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:397789 HCAPLUS

DOCUMENT NUMBER: 148:239026

TITLE: A cost effective process for production of carvedilol

INVENTOR(S): Shankar, Sanganabhatla; Pandurang, Suryavanshi

Jitendra; Moorthy, Koduru Ramanarasimha

PATENT ASSIGNEE(S): Wanbury Limited, India SOURCE: Indian Pat. Appl., 8pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

10553957

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00771	А	20060825	IN 2006-MU771	20060522
PRIORITY APPLN. INFO.:			IN 2006-MU771	20060522
0 = 11 = 0 0 11 = 0 = 10 1	~- ~	c= 440 0000	0.6	

OTHER SOURCE(S): CASREACT 148:239026

AB A cost effective process for preparation of highly pure carvedilol substantially free from impurities is described herein;
1-[carbazolyl-(4)-oxy]-3-[N-benzyl-2-(2-methoxyphenoxy)-ethylamino]-propan-2-ol is catalytically hydrogenated using inexpensive catalyst like Raney Nickel and isolating crude carvedilol free from penultimate and other major impurity; which is purified in an Et acetate/methyl Et ketone to obtain pure Carvedilol.

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(a cost effective process for production of carvedilol)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154673 HCAPLUS

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-

[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT	PATENT NO.					KIND DATE				APPLICATION NO.						DATE		
WO 2004	11132	 96		A1 20041229			WO 2004-IN52						20040304					
W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,		
	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NΙ,		
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,		
	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,		
	BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,		
	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,		
	SK,	TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,		
	TD,	ΤG																
IN 2003	BMU00	647		Α		2005	0211	IN 2003-MU647						20030620				
US 2006	50270	858		A1		2006	1130		US 2	005-	5539	57		20051019				
PRIORITY APE	PLN.	INFO	.:						IN 2	003 - 1	MU64	7		A 20030620				
									IN 2	003 - 1	MU72	1		A 2	0030	717		
									WO 2	004-	IN52		•	W 2	0040	304		
OTHER SOURCE GI	HER SOURCE(S):				WO 2004-IN52 W 200 CASREACT 142:93675; MARPAT 142:93675													

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof

with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to 70-75° for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous

layer was separated, and the product enriched organic layer was washed with water $\ensuremath{\mathsf{water}}$

till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at $3.5-4.5~{\rm Kg/cm2}$ at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 224782-73-4P, (S)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol 224782-76-7P,

(R)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 224782-73-4 HCAPLUS

CN

2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

10553957

Absolute stereochemistry. Rotation (+).

ΙT 72955-94-3P, N-Benzylcarvedilol

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of

RN

N-benzylcarvedilol)
72955-94-3 HCAPLUS
2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm CN ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

OMe

REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l14 ibib abs hitstr tot

L14 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 14 ibib abs hitstr tot

ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

2007:397789 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 148:239026

TITLE: A cost effective process for production of carvedilol

INVENTOR(S): Shankar, Sanganabhatla; Pandurang, Suryavanshi

Jitendra; Moorthy, Koduru Ramanarasimha

PATENT ASSIGNEE(S): Wanbury Limited, India SOURCE: Indian Pat. Appl., 8pp.

CODEN: INXXBQ

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2006MU00771 PRIORITY APPLN. INFO.:	A	20060825	IN 2006-MU771 IN 2006-MU771	20060522 20060522

OTHER SOURCE(S): CASREACT 148:239026

A cost effective process for preparation of highly pure carvedilol substantially free from impurities is described herein; 1-[carbazolyl-(4)-oxy]-3-[N-benzyl-2-(2-methoxyphenoxy)-ethylamino]-propan-2-ol is catalytically hydrogenated using inexpensive catalyst like Raney Nickel and isolating crude carvedilol free from penultimate and other major impurity; which is purified in an Et acetate/methyl Et ketone to obtain pure Carvedilol.

72955-94-3P ΙT

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(a cost effective process for production of carvedilol)

RN

72955-94-3 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm CN ethyl)amino]- (CA INDEX NAME)

PAGE 2-A



L4 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:845541 HCAPLUS

DOCUMENT NUMBER: 145:505330

TITLE: Synthesis of carvedilol via method which inhibits

formation of impurities

INVENTOR(S): Byun, Il Suk; Chang, Suk Ku; Kim, Wan Joo; Kim, Young

Youn; Lee, Woo Hwa; Oh, Chun Rim; Ryu, Jung Bok

PATENT ASSIGNEE(S): Chemtech Research Incorporation, S. Korea

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Facent Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005003764	A	20050112	KR 2003-45256	20030704

PRIORITY APPLN. INFO.:

KR 2003-45256

20030704

AB A method for preparing carvedilol [i.e., 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol] is provided, thereby inhibiting formation of impurities. The highly pure product is useful for the treatment of hypertension. The method for preparing carvedilol thus comprises the reaction of a 1-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanone derivative with 9H-4-hydroxycarbazole. The resulting intermediate then reduced and debenzylated to give the target compound. The debenzylation of the reduced intermediate is carried out using a catalyst in presence of base, such as potassium carbonate, sodium carbonate, potassium hydride or sodium hydride.

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol via method which inhibits formation of impurities using [(methoxyphenoxy)ethyl]amino]propanone derivative and (hydroxy)carbazole as reactants and reaction sequence involving alkylation, reduction and debenzylation)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

OMe

L4 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1338355 HCAPLUS

DOCUMENT NUMBER: 144:419905

TITLE: Determination of carvedilol and its impurities in

pharmaceuticals

AUTHOR(S): Stojanovic, J.; Marinkovic, V.; Vladimirov, S.;

Velickovic, D.; Sibinovic, P.

CORPORATE SOURCE: 'Zdravlje-Actavis', Pharmaceutical and Chemical

Industry, Leskovac, 16000,

SOURCE: Chromatographia (2005), 62(9/10), 539-542

CODEN: CHRGB7; ISSN: 0009-5893

PUBLISHER: Vieweg Verlag/GWV Fachverlage GmbH

DOCUMENT TYPE: Journal LANGUAGE: English

AB A reversed-phase high-performance liquid chromatog. (RP-HPLC) method was developed for separation of carvedilol and its impurities from Karvileks tablets. The best separation was achieved on a 100 mm + 4.6 mm, 5 μm particle size, Chromolit RP 8e column. Use of acetonitrile-water, 45:55 (volume/volume), adjusted to pH 2.5 with formic acid, as mobile phase at a flow rate of 0.5 mL min-1 enabled acceptable resolution of carvedilol, in large excess, from possible impurities, in a short elution time. UV detection was performed at 280 nm. Linearity, accuracy, precision, selectivity, and robustness were validated and found to be satisfactory. Overall, the proposed method was found to be highly sensitive, suitable, and accurate for quant. determination of carvedilol and its impurities in dosage

forms and in raw materials.

IT 72955-94-3

RL: ANT (Analyte); FMU (Formation, unclassified); ANST (Analytical study); FORM (Formation, nonpreparative)

(determination of carvedilol and its impurities in pharmaceuticals)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1260624 HCAPLUS

DOCUMENT NUMBER: 144:22806

TITLE: Process for the preparation of carvedilol INVENTOR(S): Kankan, Rajendra Narayanrao; Rao, Dharmaraj

Ramachandra

PATENT ASSIGNEE(S): Cipla Limited, India; Wain, Christopher Paul

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

GΙ

```
20051201
                                            WO 2005-GB1978
     WO 2005113502
                          Α1
                                                                    20050519
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2005245182
                                20051201
                                            AU 2005-245182
                          A1
                                                                    20050519
     CA 2566197
                                20051201
                                            CA 2005-2566197
                                                                    20050519
                          Α1
     EP 1756057
                                20070228
                                            EP 2005-744187
                                                                    20050519
                          Α1
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     JP 2007538061
                          Τ
                                20071227
                                            JP 2007-517424
                                                                    20050519
     IN 2006MN01302
                          Α
                                20070608
                                             IN 2006-MN1302
                                                                    20061107
PRIORITY APPLN. INFO.:
                                             GB 2004-11273
                                                                 Α
                                                                    20040520
                                                                 W 20050519
                                             WO 2005-GB1978
OTHER SOURCE(S):
                         CASREACT 144:22806
```

AB A process for the preparation of carvedilol I (R = H) was disclosed and comprised aromatization/reduction of 1,2,3,9-tetrahydro-4H-carbazol-4-one by refluxing with Raney Ni and NaOH in water for 20 h to form 4-hydroxy-9H-carbazole, reaction of resulting alc. with epichlorohydrin using tetrabutylammonium bromide and NaOH in water to give 4-oxiranylmethoxy-9H-carbazole, reaction of the intermediate epoxide with MeO-2-C6H4O(CH2)2NHCH2Ph using K2CO3 in water to give carvedilol N-benzyl derivative I (R = CH2Ph), and finally, debenzylation of I (R = CH2Ph) using Pd/C in EtOAc and water to give the desired carvedilol. This invention further provided carvedilol prepared by the disclosed process, and pharmaceutical compns. containing the same, for therapeutic uses, such as adrenergic β -receptor antagonists, vasodilators and treatment of angina pectoris.

Ι

IT 72955-94-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carvedilol for use in pharmaceutical compns. as adrenergic $\beta\text{--receptor}$ antagonists and vasodilators useful for the treatment of hypertension and angina pectoris)

RN 72955-94-3 HCAPLUS

2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm CN ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

2005:1128799 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 143:386916

An improved process for the manufacture of carvedilol TITLE:

INVENTOR(S): Kankan, Rajendra Narayan Rao; Rao, Dharamraj

Ramchandra

Cipla Ltd., India PATENT ASSIGNEE(S): Indian, 11 pp. CODEN: INXXAP SOURCE:

Patent

DOCUMENT TYPE: English LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 186587	A1	20011006	IN 1999-BO583	19990817
PRIORITY APPLN. INFO.:			IN 1999-BO583	19990817
OTHER SOURCE(S):	CASREA	ACT 143:38691	.6; MARPAT 143:386916	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB An improved process for the manufacture of Carvedilol I, a potent antihypertensive (no biol. data given) by catalytic hydrogenation of N-substituted Carvedilol II [R1 = (un)substituted CH2Ph; formed by reacting carbazole III with a substituted amine IV]. Thus, N-alkylating benzylamine with 2-(2-methoxyphenoxy)ethyl bromide followed by reaction of the resulting N-[2-(2-methoxyphenoxy)ethyl]benzenemethanamine hydrochloride with 4-(2,3-epoxypropoxy)carbazole, and subsequent hydrogenation of the II [R1 = Ch2Ph] afforded carvedilol I.

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

OMe

ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

2004:1154673 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 142:93675

TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-

[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol

INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev;

Thennati, Rajamannar

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

PCT Int. Appl., 27 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	PATENT NO.					KIND DATE				APPLICATION NO.						DATE		
WC	WO 2004113296				A1					WO 2	004-	20040304						
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MΖ,	NA,	NI,	
		NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	
		ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW	
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	
		BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
		ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	ΙT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	
		SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	
		TD,	ΤG															
IN	IN 2003MU00647			Α		2005	0211	IN 2003-MU647						20030620				
US	US 20060270858			A1		2006	1130	US 2005-553957						20051019				
PRIORIT	PRIORITY APPLN. INFO.:							IN 2003-MU647						A 20030620				
										IN 2	003-1	MU72	1		A 2	0030	717	
									,	WO 2	004-	IN52		1	W 2	0040	304	
OTHER SOURCE(S): GI				CASI	REAC	T 14.	2:93	675 ;	MAR	PAT	142:	9367	5					

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- AΒ The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer

or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to 70-75° for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and

the

product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature $60-70^{\circ}$ for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

IT 224782-73-4P, (S)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]- 3-[(9H-carbazol-4-yl)oxy]propan-2-ol 224782-76-7P, (R)-1-[N-Benzyl-N-[2-(2-methoxyphenoxy)ethyl]amino]-3-[(9H-carbazol-4-yl)oxy]propan-2-ol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of carvedilol by amination of oxiranylmethoxycarbazole with N-(methoxyphenoxyethyl)benzylamine and hydrogenolysis of N-benzylcarvedilol)

RN 224782-73-4 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

ΙT 72955-94-3P, N-Benzylcarvedilol RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carvedilol by amination of oxiranylmethoxycarbazole with $\ensuremath{\mathtt{N-}}$ (methoxyphenoxyethyl) benzylamine and hydrogenolysis of N-benzylcarvedilol)

72955-94-3 HCAPLUS 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm CN ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:556143 HCAPLUS

DOCUMENT NUMBER: 137:125080

TITLE: Process for preparing heterocyclic indene analogs by

cyclocarbonylation at moderate temperatures and

catalyst loading

INVENTOR(S): Scalone, Michelangelo; Zeibig, Thomas Albert

PATENT ASSIGNEE(S): Hoffmann-LaRoche Inc., Switz. SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.			KIND DATE			APPLICATION NO.					DATE						
US	2002	0099	 223		A1 20020725					US 2002-54462				20020122			
	6777						2004										
	2434						20020801 CA 2002-2434408										
									WO 2002-EP583						20020122		
WO	2002				_												
	W:										3, BG,						
											C, EE,						
											E, KG,						
		•		•			•	•	•		1, MW,	•	•	,			•
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SI	, TJ,	TM,	TR,	TT,	TZ,	UA,	UG,
			,	,	ZA,												
	RW:										z, TZ,						
											E, IT,						
		•		,		,	,	,	,	_	Q, GW,		,	,			
AU 2002247645																	
EP											2002-						
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GF	R, IT,	LI,	LU,	NL,	SE,	MC,	PT,
											J, TR						
JP 2004519465						JP 2002-559391						20020122					
	4056						2008										
ΙN	2003	CN01	126		A		2005	0422		ΙN	2003-	CN11	26		2	0030	722
											2003-					0030	723
US	2004	0127	723		A1		2004	0701		US	2004-	7632	96		2	0040	122
US	7169	935			В2		2007	0130									
TIRC	Y APP	LN.	INFO	.:						EΡ	2001-	1015	84		A 2	0010	125
										US	2002-	5446	2		A3 2	0020	122
										WO	2002-	EP58	3		W 2	0020	122
ER SO	DURCE	(S):			CASI	REAC	T 13	7:12	5080	: N	(ARPAT	137	:125	080			

OTHER SOURCE(S): CASREACT 137:125080; MARPAT 137:125080

 $\mbox{\sc AB}$ $\mbox{\sc A}$ process for the preparation heterocyclic indene analogs, especially with the preparation

10553957

of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification This process avoids high temps.

and

high catalyst loadings.

IT 72955-94-3P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; process for preparing heterocyclic indene analogs by cyclocarbonylation at moderate temps. and catalyst loading)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

REFERENCE COUNT:

4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:747162 HCAPLUS

DOCUMENT NUMBER: 135:288690

```
Intermediates for preparing the R- or S- enantiomer
TITLE:
                            and N-benzyl derivatives of 1-[9'H-carbazol-4'-yloxy]-
                            3-[2"-(2"'-methoxyphenoxy)ethylamino]propan-2-ol
                            [carvedilol]
INVENTOR(S):
                            Ratkai, Zoltan; Barkoczy, Jozsef; Simig, Gyula;
                            Gregor, Tamas; Vereczkey, Gyoergyi Donath; Nemeth,
                            Norbert; Nagy, Kalman; Cselenyak, Judit; Szabo, Tibor;
                            Balazs, Laszlo; Doman, Imre; Greff, Zoltan; Nagy,
                            Peter Kotay; Seres, Peter
PATENT ASSIGNEE(S):
                            Egis Gyogyszergyar Rt., Hung.
                            Eur. Pat. Appl., 9 pp.
SOURCE:
                            CODEN: EPXXDW
DOCUMENT TYPE:
                            Patent
                            English
LANGUAGE:
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:
                        KIND DATE APPLICATION NO.
     PATENT NO.
                                                  _____
                                                                             _____
     EP 1142874 A2 20011010
EP 1142874 A3 20031022
                                                 EP 2001-111214
                                                                            19981124
         R: BE, DE, ES, FR, GB, IT, SI, LT, LV, RO
     HU 9802180 A1 20001228 HU 1998-2180

RU 2216539 C2 20031120 RU 1998-120700

RU 2245875 C2 20050210 RU 2003-107772

EP 918055 A1 19990526 EP 1998-122114

EP 918055 B1 20030423

EP 918055 B2 20060426
                                                                             19981001
                                                 RU 1998-120700
RU 2003-107772
EP 1998-122114
                                                                             19981118
                                                                             19981118
                                                                             19981124
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO

      HU 1997-2209
      A 19971124

      HU 1998-2180
      A 19981001

      EP 1998-122114
      A3 19981124

      RU 1998-120700
      A 19981118

PRIORITY APPLN. INFO.:
OTHER SOURCE(S):
                            CASREACT 135:288690
     R-(+)-1-[N-benzyl-2'-[[2''-(methoxyphenoxy)ethyl]amino]-3-[9'''H-carbazol-1]
     4'''-yloxy]propan-2-ol and S-(-)-1-[N-benzyl-2'-[[2''-
     (methoxyphenoxy)ethyl]amino]-3-[9'''H-carbazol-4'''-yloxy]propan-2-ol and
     the R- or S- enantiomer of carvedilol are prepared in high yield and
     selectivity by the ring-opening cleavage of the resp. R- or S- enantiomer
     of 4-(oxiranylmethoxy)-9H-carbazole with N-2-[(2'-
     methoxyphenoxy)ethyl]benzylamine to give the N-benzyl derivs., and the
     chiral carvedilol enantiomers are prepared by the reductive debenzylation of
     the resp. chiral N-benzyl derivs. in the presence of Pd/C and hydrazine
     hydrate.
     224782-76-7P
ΙT
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
      (Reactant or reagent)
         (intermediates for preparing the R- or S- enantiomer and N-benzyl derivs.
         of 1-[9'H-carbazol-4'-yloxy]-3-[2"-(2"'-methoxyphenoxy)ethylamino]propa
```

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

n-2-ol [carvedilol])

10553957

RN 224782-73-4 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-73-4 HCAPLUS


CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:747161 HCAPLUS

DOCUMENT NUMBER: 135:288689

TITLE: Process for preparing 1-[9'H-carbazol-4'-yloxy]-3-[2"-

(2"'- methoxyphenoxy)ethylamino]-propan-2-ol

[carvedilol]

INVENTOR(S): Ratkai, Zoltan; Barkoczy, Jozsef; Simig, Gyula;

Gregor, Tamas; Vereczkey, Gyoergyi Donath; Nemeth, Norbert; Nagy, Kalman; Cselenyak, Judit; Szabo, Tibor;

Balazs, Laszlo; Doman, Imre; Greff, Zoltan; Nagy,

Peter Kotay; Seres, Peter

PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.

SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
EP 1142873
                                               A2
                                                               20011010
                                                                                    EP 2001-111213
                                                                                                                                    19981124
         EP 1142873
                                                АЗ
                                                               20030910
         EP 1142873
                                                 В1
                                                               20040421
                R: BE, DE, ES, FR, GB, IT, SI, LT, LV, RO
         HU 9802180
                                  A1 20001228
                                                                                                                                    19981001
                                                                                      HU 1998-2180
                                                                                                                                    19981118
         RU 2216539
                                                  C2
                                                              20031120
                                                                                      RU 1998-120700
                                                C2
         RU 2245875
                                                              20050210
                                                                                      RU 2003-107772
                                                                                                                                    19981118
         EP 918055
                                                  A1
                                                              19990526
                                                                                      EP 1998-122114
                                                                                                                                    19981124
         EP 918055
                                                  В1
                                                              20030423
         EP 918055
                                                  В2
                                                             20060426
                 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                         IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.:
                                                                                       HU 1997-2209
                                                                                                                              A 19971124
                                                                                       HU 1998-2180
                                                                                                                              A 19981001
                                                                                       EP 1998-122114
                                                                                                                              A3 19981124
                                                                                                                              A 19981118
                                                                                       RU 1998-120700
OTHER SOURCE(S):
                                                 CASREACT 135:288689
         A process for preparing 1-[9'H-carbazol-4'-yloxy]-3-[{2'-(2'-
         methoxyphenoxy)ethyl}amino]propan-2-ol as well as acid addition salts of this
         compound, was developed in which the N-[2-(2'-methoxy-phenoxy)-
         ethyl]benzylamine is reacted with epichlorohydrin, and the formed
         1-N-benzyl-2'-[{(2'-methoxy-phenoxy)ethyl}amino]-3-propan-2-ol is reacted
         with 4-hydroxy-9H-carbazole and the resulting 1-N-benzyl-2'-
          (methoxyphenoxyethylamino)-3-[9'H-carbazol-4'-yloxy]propan-2-ol is
         debenzylated by catalytic hydrogenation and, if desired, the
         1-[9'H-carbazol-4'-yloxy]-3-[{2'-(2'-methoxyphenoxy)ethyl}amino]propan-2-
         ol thus obtained is reacted with acids to yield acid addition their salts, or
         if desired, liberating the free 1-[9'H-carbazol-4'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[\{2\}-(2'-yloxy]-3-[[2]-(2'-yloxy]-3-[[2]-(2'-yloxy]-3-[[2]-(2'-yloxy]-3-[[2]-(2'-yloxy]-3-[[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy]-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]-(2'-yloxy)-3-[2]
         methoxyphenoxy)ethyl]aminopropan-2-ol base from acid addition salts thereof
         and, if desired, converting the free 1-[9'H-carbazol-4'-yloxy]-3-\{2\}-(2'-yloxy)
         methoxyphenoxy)ethylamino-propan-2-ol base into other acid addition salts
         and/or, if desired, separating the enantiomers.
         72955-94-3P
ΤТ
         RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
         preparation); PREP (Preparation); RACT (Reactant or reagent)
                (process for preparing 1-[9'H-carbazol-4'-yloxy]-3-[2-(2'-
               methoxyphenoxy)ethylamino]propan-2-ol [carvedilol])
RN
         72955-94-3 HCAPLUS
         2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm
CN
```

ethvl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A



ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:344783 HCAPLUS

DOCUMENT NUMBER: 130:352184

Preparation of carvedilol TITLE:

INVENTOR(S):

Ratkai, Zoltan; Barkoczy, Jozsef; Simig, Gyula; Gregor, Tamas; Vereczkey, Gyorgyi Donath; Nemeth, Norbert; Nagy, Kalman; Cselenyak, Judit; Szabo, Tibor; Balazs, Laszlo; Doman, Imre; Greff, Zoltan; Nagy,

Peter Kotay; Seres, Peter Egis Gyogyszergyar Rt., Hung.

PATENT ASSIGNEE(S): SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

EP	918055			A1	19990526	EP 1998-122114	19981124
EP	918055			В1	20030423		
EP	918055			В2	20060426		
	R: AT,	BE,	CH,	DE,	DK, ES, FR,	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
	IE,	SI,	LT,	LV,	FI, RO		
HU	9802180			A1	20001228	HU 1998-2180	19981001
CZ	296521			В6	20060412	CZ 1998-3561	19981104
CZ	297445			В6	20061213	CZ 2004-1111	19981104
HR	980590			В1	20031231	HR 1998-590	19981112
SK	284109			В6	20040908	SK 1998-1560	19981112
RU	2216539			C2	20031120	RU 1998-120700	19981118
RU	2245875			C2	20050210	RU 2003-107772	19981118
EP	1142873			A2	20011010	EP 2001-111213	19981124
EP	1142873			А3	20030910		
EP	1142873			В1	20040421		
	R: BE,	DE,	ES,	FR,	GB, IT, SI,	LT, LV, RO	
EP	1142874			A2		EP 2001-111214	19981124
EP	1142874			А3			
					GB, IT, SI,		
	2196459			Т3		ES 1998-122114	19981124
_	2221875			Т3	20050116	ES 2001-111213	19981124
PRIORIT	Y APPLN.	INFO	.:				A 19971124
							A 19981001
							A 19981118
						EP 1998-122114	A3 19981124

AB The title process comprises, e.g., condensation of 4-oxiranylmethoxy-9H-carbazole with 2-(MeO)C6H4OCH2CH2NHCH2Ph in a protic organic solvent followed by deprotection.

TT 72955-94-3P 224782-73-4P 224782-76-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of carvedilol)

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A


RN 224782-73-4 HCAPLUS
CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylmethyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 224782-76-7 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](phenylm ethyl)amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:270010 HCAPLUS

DOCUMENT NUMBER: 120:270010

TITLE: Synthesis of the enantiomers and three racemic

metabolites of Carvedilol labeled to high specific

activity with tritium

AUTHOR(S): Senderoff, S. G.; Villani, A. J.; Landvatter, S. W.;

Garnes, K. T.; Heys, J. R.

CORPORATE SOURCE: Dep. Synth. Chem., SmithKline Beecham Pharm., King of

Prussia, PA, 19406, USA


SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals

(1993), 33(12), 1091-105

CODEN: JLCRD4; ISSN: 0362-4803

DOCUMENT TYPE: Journal LANGUAGE: English

GΙ



AB Carvedilol (SK&F 105517) (I) possesses unique cardiovascular activity, and is under development for indications such as angina and hypertension. Tritium labeled enantiomers of Carvedilol and racemates of three metabolites were needed for pharmacol. and drug metabolic studies. These compds. were synthesized by catalytic tritium-halogen exchange using tritium gas and 10% palladium-on-carbon catalyst. The precursors were

polyhalogenated in the carbazole ring. Direct electrophilic bromination of the enantiomers of Carvedilol gave precursors that were converted to the corresponding tritiated final products by catalytic tritium halogen exchange. Bromination of 4-(2,3-epoxypropyloxy)-9H-carbazole gave an intermediate that was converted to the halogenated precursors of the racemic metabolites. Elaboration of this intermediate, 1,3,6-tribromo-4-(2,3-epoxypropyloxy)-9H-carbazole, to the desired metabolite precursors was achieved by nucleophilic epoxide opening with suitably functionalized N-benzyl aryloxyethylamines. Catalytic tritium-halogen exchange upon the brominated metabolite precursors was accompanied by cleavage of N- and O-benzyl protecting groups. Radiochem. purities of all tritiated final products were greater than 98% after preparative HPLC. Specific activities of the final products, determined by mass spectrometry, ranged from 35 to 76 Ci/mmol. Optical purity of the Carvedilol enantiomers, determined by chiral HPLC, was greater than 99%.

IT 154582-54-4P 154582-58-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (intermediate in preparation of tritium labeled Carvedilol)

RN 154582-54-4 HCAPLUS

CN Phenol, 3-[2-[[2-hydroxy-3-[(1,3,6-tribromo-9H-carbazol-4-yl)oxy]propyl](phenylmethyl)amino]ethoxy]-4-methoxy- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

RN 154582-58-8 HCAPLUS

CN Phenol, 4-[2-[[2-hydroxy-3-[(1,3,6-tribromo-9H-carbazol-4-yl)oxy]propyl](phenylmethyl)amino]ethoxy]-3-methoxy- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

IT 154582-61-3P

RN 154582-61-3 HCAPLUS

CN Phenol, 3-[2-[[3-(9H-carbazol-4-yl-1,3,6-t3-oxy)-2-hydroxypropyl](phenylmethyl)amino]ethoxy]-4-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L4 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:128716 HCAPLUS

DOCUMENT NUMBER: 92:128716

ORIGINAL REFERENCE NO.: 92:20983a,20986a

TITLE: Carbazolyl-4-oxypropanolamine derivatives

INVENTOR(S): Wiedemann, Fritz; Kampe, Wolfgang; Thiel, Max; Sponer,

Gisbert; Roesch, Egon; Dietmann, Karl

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger. Offen., 27 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent LANGUAGE: German FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
DE 2815926	A1	19791018	DE 1978-2815926		19780413	
CA 1129416	A1	19820810			19790402	
DK 7901419	A	19791014			19790406	
DK 154555	В	19881128				
DK 154555	C	19890619				
FI 7901142	A B C	19791014	FI 1979-1142		19790406	
FI 70406	В	19860327				
FI 70406	С	19860912				
AU 7945820	A	19791018			19790406	
AU 522975	В2	19820708				
ES 479396	A1	19800416			19790406	
SU 810079	A3	19810228			19790406	
EP 4920		19791031			19790407	
EP 4920		19810805				
R: BE, CH, DE,	FR, GB	, IT, LU,	NL, SE			
IL 57020 DD 143607 CS 227007 JP 54157558 JP 01023462	A	19820730	IL 1979-57020		19790408	
DD 143607	A5	19800903	DD 1979-212096 CS 1979-2434 JP 1979-43119		19790409	
CS 227007	В2	19840416	CS 1979-2434		19790410	
JP 54157558	A	19791212			19790411	
JP 01023462	В	19890502				
4A 1901132	Δ.	17000320			19790411	
HU 21840	A2	19820227			19790412	
HU 179433		19821028				
AT 7902762	A -	19840115			19790412	
AT 375639 CS 227047 US 4503067	В	19840827				
CS 227047	B2	19840416	CS 1982-6106		19820820	
US 450306 /	A	19850305			19830404	
	A	19881025	JP 1987-76548	-	198/0331	
PRIORITY APPLN. INFO.:			DE 1978-2815926	A	19/80413	
			US 1979-21394			
			CS 1979-2434			
OTHER SOURCE(S):	MM DD 2 m	00.10071	US 1980-198975	ΑI	19801071	
OTHER SOURCE(S):	MAKPAT	97:178/1	Ю			

(preparation and acetylation of)

GΙ

^{*} STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A wide range of I (R = H, lower alkyl, or aroyl; R1 = H, lower alkyl, or aralkyl, R2 and R3 independently were H or lower alkyl, X = CH2, O, S, or valence bond; Ar = mono- or bicyclic aryl or pyridyl) (.apprx.50 compds.) were prepared as β -sympatholytics and vasodilators (no data), in most cases by reaction of 4-(oxiranylmethoxy)carbazole (II) with an amine. Thus, 6.0 g II and 7.6 g 2-MeOC6H4CH2CH2NH2 were stirred 20 h at 70° to give 61% III. Also prepared were, e.g., IV and V.

RN 72955-94-3 HCAPLUS

CN 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] (phenylm ethyl)amino]- (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

=> LOG Y COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 160.39 338.96 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -19.20 -19.20

STN INTERNATIONAL LOGOFF AT 12:13:33 ON 10 APR 2008